MaxCyte to consolidate two of its lines of shares
13th May 2021 11:22
(Sharecast News) - Cell engineering company MaxCyte announced the consolidation of two of its lines of common stock into a single unrestricted line of common stock on Thursday.
Read moreMaxCyte reports good performance despite Covid challenges
20th Apr 2021 09:22
(Sharecast News) - Cell engineering technology company MaxCyte reported a 21% year-on-year improvement in revenues in its final results on Tuesday, to $26.2m (£18.74m), despite the challenges of the Covid-19 pandemic.
Read moreMaxCyte raises £40m from new and existing investors
4th Feb 2021 09:41
(Sharecast News) - Cell engineering and life sciences company MaxCyte has announced a subscription to raise £40m, in a bid to strengthen its balance sheet.
Read moreMaxCyte appoints Amanda Murphy as CFO
9th Sep 2020 09:35
(Sharecast News) - Life sciences company MaxCyte named Amanda Murphy as its chief financial officer on Wednesday, succeeding long-time CFO Ron Holtz.
Read moreMaxCyte to consolidate stock to single trading line
21st Feb 2020 11:53
(Sharecast News) - Life sciences company MaxCyte announced the consolidation of its two lines of common stock into a single unrestricted line of common stock on Friday.
Read moreMaxCyte 'exceptionally positive' following strong FY trading performance
20th Jan 2020 10:58
(Sharecast News) - Clinical-stage life sciences company MaxCyte told investors on Monday that its board was "exceptionally positive" of the group's future following a stellar year.
Read moreMaxCyte inks new development agreement with KSQ Therapeutics
4th Dec 2019 16:14
(Sharecast News) - Cell-based therapeutics and life sciences company MaxCyte has entered into a new development and commercialisation agreement with its existing partner KSQ Therapeutics, it announced on Wednesday.
Read moreMaxCyte strikes deal with oncology company Vor Biopharma
21st Nov 2019 16:40
(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licence agreement with oncology company Vor Biopharma on Thursday, under which Vor would use MaxCyte's 'Flow Electroporation' technology to produce engineered hematopoietic stem cells (eHSCs), and initiate investigational new drug-enabling studies to accelerate its progress towards the clinic.
Read moreSunday share tips: IQE, MaxCyte
26th May 2019 21:53
(Sharecast News) - In his 'Inside the City' column for The Sunday Times, Ben Woods looked at the effect of Donald Trump's posturing against Huawei on the chipmaking industry - particularly, wafer semiconductor technology minnow IQE.
Read moreMaxCyte begins dosing second cohort in MCY-M11 clinical trial
8th May 2019 15:58
(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.
Read moreMaxCyte launches new generation of cellular engineering instruments
8th Apr 2019 08:34
(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.
Read more